Hypopituitarism secondary prevention

	Hypopituitarism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hypopituitarism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hypopituitarism secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hypopituitarism secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hypopituitarism secondary prevention
CDC on Hypopituitarism secondary prevention
Hypopituitarism secondary prevention in the news
Blogs on Hypopituitarism secondary prevention
Directions to Hospitals Treating Hypopituitarism
Risk calculators and risk factors for Hypopituitarism secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2] , Ahmed Elsaiey, MBBCH [3]

Overview

Secondary prevention may be done by long term monitoring of patients for complications of hormonal replacement therapy and by dose adjustments in stressful situations.

Secondary prevention may be done by long term monitoring of patients:
- For complications of hormonal replacement therapy (under-replacement/over replacement)^[1]
- By adjusting the dosages in stressful situations

↑ Harsch IA, Schuller A, Hahn EG, Hensen J (2010). "Cortisone replacement therapy in endocrine disorders - quality of self-care". J Eval Clin Pract. 16 (3): 492–8. doi:10.1111/j.1365-2753.2009.01149.x. PMID 20210825.